CN101084008A - 角质形成细胞生长因子的治疗制剂 - Google Patents
角质形成细胞生长因子的治疗制剂 Download PDFInfo
- Publication number
- CN101084008A CN101084008A CNA2005800433149A CN200580043314A CN101084008A CN 101084008 A CN101084008 A CN 101084008A CN A2005800433149 A CNA2005800433149 A CN A2005800433149A CN 200580043314 A CN200580043314 A CN 200580043314A CN 101084008 A CN101084008 A CN 101084008A
- Authority
- CN
- China
- Prior art keywords
- kgf
- compositions
- growth factor
- keratinocyte growth
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Abstract
Description
重构溶液中的稀释剂 | 重构后的视觉观察 |
0.1%聚山梨酯200.01%聚山梨酯200.004%聚山梨酯200.001%聚山梨酯20水 | 澄清但有泡沫澄清少数颗粒/边界颗粒颗粒 |
Claims (31)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63621004P | 2004-12-15 | 2004-12-15 | |
US60/636,210 | 2004-12-15 | ||
PCT/US2005/045169 WO2006065861A2 (en) | 2004-12-15 | 2005-12-12 | Therapeutic formulations of keratinocyte growth factor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101084008A true CN101084008A (zh) | 2007-12-05 |
CN101084008B CN101084008B (zh) | 2013-04-10 |
Family
ID=36337531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800433149A Expired - Fee Related CN101084008B (zh) | 2004-12-15 | 2005-12-12 | 角质形成细胞生长因子的治疗制剂 |
Country Status (28)
Country | Link |
---|---|
US (1) | US8304387B2 (zh) |
EP (1) | EP1827483B1 (zh) |
JP (1) | JP5201992B2 (zh) |
KR (1) | KR101283736B1 (zh) |
CN (1) | CN101084008B (zh) |
AR (1) | AR052339A1 (zh) |
AU (1) | AU2005317166B2 (zh) |
BR (1) | BRPI0519070A2 (zh) |
CA (1) | CA2589889C (zh) |
CR (1) | CR9246A (zh) |
DK (1) | DK1827483T3 (zh) |
EA (1) | EA013369B1 (zh) |
ES (1) | ES2504441T3 (zh) |
HK (1) | HK1115298A1 (zh) |
HR (1) | HRP20140926T1 (zh) |
IL (1) | IL183435A (zh) |
MX (1) | MX2007006822A (zh) |
MY (1) | MY145638A (zh) |
NO (1) | NO20073629L (zh) |
NZ (1) | NZ555503A (zh) |
PL (1) | PL1827483T3 (zh) |
PT (1) | PT1827483E (zh) |
RS (1) | RS53548B1 (zh) |
SI (1) | SI1827483T1 (zh) |
TW (1) | TWI351966B (zh) |
UA (1) | UA88497C2 (zh) |
WO (1) | WO2006065861A2 (zh) |
ZA (1) | ZA200706095B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102379838A (zh) * | 2011-11-02 | 2012-03-21 | 广州舒泰生物技术有限公司 | 一种舒缓静颜化妆品的制备方法及应用 |
WO2012122859A1 (zh) * | 2011-03-17 | 2012-09-20 | 重庆富进生物医药有限公司 | 人角质细胞生长因子-ⅰ二硫键变构体及其制备方法和应用 |
CN107041948A (zh) * | 2009-01-21 | 2017-08-15 | 北京三有利科技发展有限公司 | 细胞生长因子治疗溃疡性疾病和肺纤维化疾病的应用 |
CN108359634A (zh) * | 2018-02-02 | 2018-08-03 | 江阴司特易生物技术有限公司 | 一种饲养细胞蛋白复合物及其应用 |
CN109402130A (zh) * | 2018-11-23 | 2019-03-01 | 成都中医药大学附属医院 | 一种重组人角质细胞生长因子-1及其制备方法和用途 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1827483E (pt) | 2004-12-15 | 2014-09-25 | Swedish Orphan Biovitrum Ab Publ | Formulações terapêuticas do fator de crescimento de queratinócitos |
US20090186805A1 (en) * | 2006-07-06 | 2009-07-23 | Aaron Thomas Tabor | Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance |
KR100784134B1 (ko) * | 2006-10-09 | 2007-12-12 | 주식회사 대웅 | 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물 |
IT1396020B1 (it) * | 2009-10-16 | 2012-11-09 | Fitologica Srl | Composizione topica a base di biopeptidi, e suo utilizzo in campo tricologico. |
US20140287995A1 (en) * | 2011-11-02 | 2014-09-25 | The University Of Chicago | Stable pharmaceutical formulations of growth factor peptides |
US20150126433A1 (en) * | 2012-04-25 | 2015-05-07 | University Of Cincinnati | Growth factors for the treatment of mycobacterial infection |
AU2014228938B2 (en) | 2013-03-15 | 2019-05-02 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
CN110339345B (zh) * | 2019-07-30 | 2022-11-29 | 重庆派金生物科技有限公司 | 一种重组人截短型角质细胞生长因子-1滴眼液及其制备方法和应用 |
EP4183796A1 (en) | 2021-11-19 | 2023-05-24 | Enantis s.r.o. | Thermostable fgf10 polypeptide or fragment thereof use thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7026291B1 (en) | 1989-01-31 | 2006-04-11 | The United States Of America As Represented By The Department Of Health And Human Services | Epithelial cell specific growth factor, keratinocyte growth factor (KGF) |
EP0555205B1 (en) | 1989-01-31 | 2000-11-29 | RUBIN, Jeffrey S | Dna encoding a growth factor specific for epithelial cells |
ATE227583T1 (de) * | 1991-12-20 | 2002-11-15 | Novo Nordisk As | Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält |
NZ266622A (en) | 1993-06-29 | 1997-10-24 | Chiron Corp | Keratinocyte growth factor fragment (kgf) with at least a 2-fold increase in mitogenic activity compared to a full length kgf; dna molecules, expression vectors, host cells, and conjugates |
US7084119B2 (en) | 1993-06-29 | 2006-08-01 | Chiron Corporation | Truncated keratinocyte growth factor (KGF) having increased biological activity |
US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
EP0804479B1 (en) | 1994-10-13 | 2006-10-11 | Amgen Inc., | Method of treating diabetes mellitus using kgf |
US6008328A (en) | 1994-10-13 | 1999-12-28 | Amgen Inc. | Method for purifying keratinocyte growth factors |
ES2196088T3 (es) | 1994-10-13 | 2003-12-16 | Amgen Inc | Analogos del factor de crecimiento de los queratinocitos. |
US6790439B1 (en) * | 1995-06-07 | 2004-09-14 | Zymogenetics, Inc. | Thrombopoietin compositions |
CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
ATE220689T1 (de) * | 1996-12-06 | 2002-08-15 | Amgen Inc | Verwendung eines kgf-proteinproduktes und eines glp-2 proteinproduktes für die herstellung eines medikamentes |
US20020012961A1 (en) * | 1999-04-15 | 2002-01-31 | Genentech, Inc. | Fibroblast growth factor- 19 |
US6238888B1 (en) * | 1997-12-22 | 2001-05-29 | Human Genone Sciences, Inc. | Keratinocyte growth factor-2 formulations |
JP2003500456A (ja) * | 1999-06-02 | 2003-01-07 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | 角質細胞増殖因子−2製剤 |
US6440414B1 (en) * | 1999-10-01 | 2002-08-27 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
PT1827483E (pt) | 2004-12-15 | 2014-09-25 | Swedish Orphan Biovitrum Ab Publ | Formulações terapêuticas do fator de crescimento de queratinócitos |
-
2005
- 2005-12-12 PT PT58539727T patent/PT1827483E/pt unknown
- 2005-12-12 DK DK05853972.7T patent/DK1827483T3/da active
- 2005-12-12 ES ES05853972.7T patent/ES2504441T3/es active Active
- 2005-12-12 JP JP2007546844A patent/JP5201992B2/ja not_active Expired - Fee Related
- 2005-12-12 US US11/302,033 patent/US8304387B2/en active Active
- 2005-12-12 PL PL05853972T patent/PL1827483T3/pl unknown
- 2005-12-12 EA EA200701293A patent/EA013369B1/ru not_active IP Right Cessation
- 2005-12-12 RS RSP20140512 patent/RS53548B1/en unknown
- 2005-12-12 BR BRPI0519070-3A patent/BRPI0519070A2/pt not_active IP Right Cessation
- 2005-12-12 MX MX2007006822A patent/MX2007006822A/es active IP Right Grant
- 2005-12-12 EP EP05853972.7A patent/EP1827483B1/en active Active
- 2005-12-12 KR KR1020077013435A patent/KR101283736B1/ko not_active IP Right Cessation
- 2005-12-12 NZ NZ555503A patent/NZ555503A/en not_active IP Right Cessation
- 2005-12-12 CN CN2005800433149A patent/CN101084008B/zh not_active Expired - Fee Related
- 2005-12-12 AU AU2005317166A patent/AU2005317166B2/en not_active Ceased
- 2005-12-12 UA UAA200707966A patent/UA88497C2/ru unknown
- 2005-12-12 CA CA2589889A patent/CA2589889C/en not_active Expired - Fee Related
- 2005-12-12 WO PCT/US2005/045169 patent/WO2006065861A2/en active Application Filing
- 2005-12-12 SI SI200531886T patent/SI1827483T1/sl unknown
- 2005-12-14 AR ARP050105231A patent/AR052339A1/es unknown
- 2005-12-15 TW TW094144470A patent/TWI351966B/zh not_active IP Right Cessation
- 2005-12-15 MY MYPI20055903A patent/MY145638A/en unknown
-
2007
- 2007-05-27 IL IL183435A patent/IL183435A/en not_active IP Right Cessation
- 2007-07-13 ZA ZA200706095A patent/ZA200706095B/xx unknown
- 2007-07-13 NO NO20073629A patent/NO20073629L/no not_active Application Discontinuation
- 2007-07-13 CR CR9246A patent/CR9246A/es unknown
-
2008
- 2008-05-06 HK HK08105042.9A patent/HK1115298A1/xx not_active IP Right Cessation
-
2014
- 2014-09-26 HR HRP20140926TT patent/HRP20140926T1/hr unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107041948A (zh) * | 2009-01-21 | 2017-08-15 | 北京三有利科技发展有限公司 | 细胞生长因子治疗溃疡性疾病和肺纤维化疾病的应用 |
WO2012122859A1 (zh) * | 2011-03-17 | 2012-09-20 | 重庆富进生物医药有限公司 | 人角质细胞生长因子-ⅰ二硫键变构体及其制备方法和应用 |
CN102379838A (zh) * | 2011-11-02 | 2012-03-21 | 广州舒泰生物技术有限公司 | 一种舒缓静颜化妆品的制备方法及应用 |
CN102379838B (zh) * | 2011-11-02 | 2013-06-12 | 广州舒泰生物技术有限公司 | 一种舒缓静颜化妆品的制备方法及应用 |
CN108359634A (zh) * | 2018-02-02 | 2018-08-03 | 江阴司特易生物技术有限公司 | 一种饲养细胞蛋白复合物及其应用 |
CN109402130A (zh) * | 2018-11-23 | 2019-03-01 | 成都中医药大学附属医院 | 一种重组人角质细胞生长因子-1及其制备方法和用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101084008B (zh) | 角质形成细胞生长因子的治疗制剂 | |
JP2000506894A (ja) | 中枢神経系の虚血または外傷の機能的回復を増大させる方法 | |
PT804479E (pt) | Método para o tratamento de diabetes mellitus utilizando kgf | |
JP2008283980A (ja) | ケラチノサイト増殖因子−2産物 | |
JP2010523501A (ja) | Ghrh分子の医薬製剤 | |
CA2272854C (en) | Keratinocyte growth factors and their use in combination with glucagon-like peptide derivatives | |
DE69738336T2 (de) | Verwendung von keratinocyte growth factor-2 | |
US6743422B1 (en) | Keratinocyte growth factor-2 products | |
WO2012029148A1 (ja) | 組換えヒト骨形成タンパク質-2凍結乾燥製剤 | |
US20030144202A1 (en) | Uses of keratinocyte growth factor-2 | |
EP1473366A1 (en) | Keratinocyte growth factor-2 products | |
EP1452205B1 (en) | Uses of keratinocyte growth factor-2 | |
MXPA99005163A (en) | Keratinocyte growth factors and uses thereof | |
CA2452540A1 (en) | Keratinocyte growth factor-2 products | |
AU2813901A (en) | Keratinocyte growth factor-2 products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1115298 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: BIOVITRUM AB Free format text: FORMER OWNER: AMGEN INC. Effective date: 20110330 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: STATE OF CALIFORNIA, THE USA TO: STOCKHOLM, SWEDEN |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110330 Address after: Stockholm Applicant after: Biovitrum AB Address before: American California Applicant before: Amgen Inc. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1115298 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130410 Termination date: 20151212 |
|
EXPY | Termination of patent right or utility model |